Contemporary coronary drug-eluting and coated stents: a mini-review
- PDF / 371,435 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 62 Downloads / 245 Views
INVITED REVIEW ARTICLE
Contemporary coronary drug‑eluting and coated stents: a mini‑review Yuichi Saito1 · Yoshio Kobayashi1 Received: 29 October 2020 / Accepted: 30 October 2020 © Japanese Association of Cardiovascular Intervention and Therapeutics 2020
Abstract Percutaneous coronary intervention has become a standard-of-care procedure in patients with acute and chronic coronary syndromes, in which coronary stent technology is commonly used. In this mini-review article, we summarize the characteristics of contemporary coronary drug-eluting and coated stents. Keywords Drug-eluting stent · Drug-coated stent · Percutaneous coronary intervention The introduction of drug-eluting stents (DES) into the armamentarium of percutaneous coronary intervention (PCI) has reduced in-stent restenosis. Currently, PCI with DES has become a standard-of-care procedure in patients with acute and chronic coronary syndromes. Table 1 lists the features of contemporary stents. The first-generation DES were made of stainless steel, while contemporary DES mainly consist of different kind of alloys such as cobalt chromium and platinum chromium. In the current generation DES, thinner struts are employed than in the first-generation DES (> 130 μm) with preserved radial strength and radio opacity. The lower strut thickness is believed to be associated with better stentrelated outcomes including target lesion revascularization, myocardial infarction, and stent thrombosis [1, 2]. The number of links (connectors) between hoops has an impact on stent flexibility, deliverability and conformability, and possibly clinical events [2]. Current generation DES include both durable and biodegradable polymer-coated stents, and the lifelong presence of durable polymer is reported to be related to chronic inflammation and neoatherosclerosis [3]. To overcome this potential limitation of durable polymer, biodegradable polymer DES have been developed. To date, numerous clinical trials have shown the safety of biodegradable polymer DES compared with durable polymer DES, but their clinical benefit is unclear [4, 5]. DES polymer is applied to the surface circumferentially or only at
the abluminal side. Limiting the polymer to the abluminal aspect of the stent reduces total polymer burden, although whether this technology leads to better clinical outcomes is also unknown. Different immunosuppressive and anti-cancer agents are used as anti-restenotic drugs in DES to inhibit smooth muscle proliferation. There is a stent that has an additional circumferential layer of anti-CD 34 antibodies on the stent struts on top of the polymer to capture circulating endothelial progenitor cells, conceptually leading to better endothelial healing. However, the clinical evidence is limited [6]. Beyond polymer-based DES, polymer-free DES and a drug-coated coronary stent have been emerged. With no polymer, abluminally coated probucol regulates the release of sirolimus in the former, while the latter has the microstructured abluminal surface in which an anti-restenotic drug is direct
Data Loading...
